Diabeloop

Name

Diabeloop

Legal name

Diabeloop SA

Website

https://diabeloop.fr

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Automated Insulin Delivery Systems

NAICS

Custom Computer Programming Services (541511)

SIC

Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industries

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC), Diabetes (General) (HLAKADAA)

Keywords

• Automated insulin delivery
• Diabetes management systems
• Closed-loop insulin pump
• Medical device software
• Continuous glucose monitoring

Headquarters

HQ city

Grenoble

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Diabeloop sells its DBLG1 medical device systems (pumps, terminals, and associated components) as Class IIb/III medical devices in European markets. Components carry a 4-year warranty.
2. Consumables and Ongoing Supply: Ongoing sales of consumables including sensors, infusion sets, and related supplies for the continuous glucose monitoring and insulin pump components of the system.
3. Algorithm Licensing: Diabeloop licenses its DBLG2 automated insulin delivery algorithm to third-party insulin pump manufacturers for integration into their devices (e.g., Sequel Med Tech's twiist pump, ViCentra's Kaleido pump). Revenue is derived from technology licensing and integration agreements with OEM partners.
4. Software Services (YourLoops): YourLoops is a CE-marked data visualization and monitoring platform for people with diabetes and their healthcare providers, generating ongoing software service revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Diabeloop develops and commercializes AI-driven automated insulin delivery (AID) systems for type 1 diabetes management. Its flagship products DBLG1 and DBLG2 use a self-learning algorithm that processes continuous glucose monitoring data every 5 minutes to automatically calculate and adjust insulin dosing, functioning as a hybrid closed-loop artificial pancreas. DBLG2 is delivered as a smartphone application integrated with Dexcom G7 CGM and partner insulin pumps, while DBLG1 uses a dedicated terminal. The company also offers the YourLoops data visualization platform and licenses its algorithm to insulin pump manufacturers.

Product overview

Diabeloop offers an integrated portfolio of automated insulin delivery (AID) systems for type 1 diabetes management. The core product is the DBLG2 system (latest generation) and its predecessor DBLG1, both featuring self-learning AI algorithms that automate insulin delivery based on real-time continuous glucose monitoring data. These systems integrate with third-party CGM sensors (Dexcom G6/G7) and insulin pumps (ViCentra Kaleido, Roche Accu-Chek Insight, Sequel twiist). The product ecosystem includes YourLoops, a CE-marked data visualization platform for patients and healthcare providers. DBL-hu addresses the pediatric and unstable diabetes segments. The company is transitioning from hardware-based terminals to a mobile-first software approach via smartphone applications.

Differentiator

Problem solved

Functional benefit

Products and services

• DBLG2 Automated Insulin Delivery System Second-generation automated insulin delivery system featuring a self-learning AI algorithm hosted directly on the patient's smartphone. Eliminates the need for a dedicated hardware terminal and integrates with Dexcom G7 CGM and compatible insulin pumps. Provides hybrid closed-loop insulin delivery with automatic adjustments every 5 minutes based on CGM data, with optional meal declaration and autonomous glycemic control.
• DBLG1 Automated Insulin Delivery System First-generation automated insulin delivery system using a dedicated terminal device (DH22 or MobiGo+) connected via Bluetooth to CGM sensors and insulin pumps. Class III medical device (DH22) or Class IIb (MobiGo+) with CE marking. The self-learning AI algorithm analyzes glucose data every 5 minutes and calculates optimal insulin dose based on each patient's personalized parameters.
• YourLoops Data Visualization Platform Class IIa CE-marked medical device platform for data visualization and remote monitoring. Enables people with diabetes and healthcare professionals to access health data, share information, and monitor treatment outcomes. Supports both patient self-management and clinician remote patient monitoring.
• DBL-hu (Highly Unstable Diabetes Solution) Automated insulin delivery solution specifically designed for type 1 diabetes patients with highly unstable or brittle diabetes. Addresses a more severe patient population requiring more advanced AID with specialized algorithms.
• Connected Insulin Pen Solutions Adaptation of Diabeloop's AI and connectivity technology for integration with connected insulin pen devices. Expands the company's portfolio beyond pump-based AID systems to include smart insulin pen delivery solutions for broader insulin therapy applications.

Quantifiable outcome

• Time in hypoglycemia: 2.04% in closed loop vs 7.06% in open loop in children aged 6-12 (Lancet Digital Health)
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Sequel Med TechcoreStrategic or Co-development Partner · 13 January 2026Sequel Med Tech and Diabeloop announced a collaboration to integrate Diabeloop's FDA-cleared DBLG2 algorithm into Sequel's twiist AID insulin pump — the first integration of Diabeloop's algorithm into a commercial insulin pump in the U.S. market. The twiist pump uses sound wave technology to measure microdoses of insulin. Product readiness expected end of 2026; initial U.S. launch planned for 2027, potentially followed by global expansion.
• Roche Diabetes CarecoreStrategic or Co-development PartnerRoche and Diabeloop partnered to integrate the DBLG1 algorithm with Roche's Accu-Chek Insight insulin pump, advancing automated insulin delivery for type 1 diabetes. The companies co-hosted webinars and presented clinical evidence demonstrating improved diabetes management outcomes.
• ViCentracoreStrategic or Co-development PartnerDiabeloop and ViCentra partnered to integrate DBLG2 with ViCentra's Kaleido insulin patch pump and Dexcom G7 CGM. ViCentra is establishing its own direct commercial entity in France, evolving the distribution model. Kaleido is described as the smallest, lightest, and most precise insulin patch pump in its category.
• Terumo CorporationcoreStrategic or Co-development PartnerJoint development agreement with exclusive distribution rights for DBLG1 in the Japanese market. Terumo brings local regulatory expertise, distribution infrastructure, and market presence in Japan as a premier medical device company.
• SOOILminorStrategic or Co-development PartnerSOOIL is listed among Diabeloop's international development partners, contributing to the company's interoperability strategy across multiple insulin pump manufacturers.
• BIOCORPminorStrategic or Co-development PartnerBIOCORP partnered with Diabeloop on connected insulin pen solutions, expanding the company's technology portfolio beyond AID systems to include smart insulin delivery devices.
• EOFlowminorStrategic or Co-development PartnerDiabeloop and EOFlow entered a co-development agreement to create a next-generation automated insulin delivery system using EOFlow's wearable insulin pump technology combined with Diabeloop's algorithm, accessible via a smartphone application.
• Novo NordiskminorStrategic or Co-development PartnerDiabeloop announced a collaboration with Novo Nordisk in March 2023 to integrate its technology with Novo Nordisk's connected insulin pens, expanding Diabeloop's AID ecosystem to include smart insulin pen delivery.
• SanofiminorStrategic or Co-development PartnerDiabeloop partnered with Sanofi for connected insulin pen solutions as part of its interoperability expansion strategy announced in April 2023.

Scale indicators8 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• Tandem Diabetes Care: US-listed maker of the t:slim X2 insulin pump with Control-IQ hybrid closed-loop algorithm, directly competing with Diabeloop in the automated insulin delivery market for type 1 diabetes, with established US commercial reach.
• Medtronic (Diabetes division): Operates the MiniMed 780G AID system integrating its own proprietary algorithm with the Guardian CGM; the largest vertically integrated incumbent in AID and a direct competitor for the same patient population Diabeloop targets.
• Insulet Corporation: Maker of the Omnipod 5 tubeless patch pump with SmartAdjust AID algorithm; competes with Diabeloop's integrated approach and is an alternative AID option for type 1 diabetes patients globally.
• Beta Bionics: Developer of the iLet bionic pancreas AID system that uses an adaptive algorithm requiring no carb counting; an emerging AID competitor pursuing similar type 1 diabetes indications and recently FDA-cleared/commercialized.
• ViCentra: Maker of the Kaleido insulin patch pump, Diabeloop's integrated pump partner for DBLG2; an emerging patch-pump competitor increasingly pursuing its own commercial presence in France.

Emerging players

• CamDiab (CamAPS): University of Cambridge spin-out commercializing the CamAPS FX adaptive hybrid closed-loop algorithm integrated with multiple pumps and CGMs in Europe; closest direct algorithmic competitor to Diabeloop's DBLG1/DBLG2.
• Sequel Med Tech: Maker of the sound wave-based twiist AID pump that Diabeloop's DBLG2 algorithm is being integrated into for the 2027 US launch; both a key US commercial partner and a competitor for AID pump share.

Broad incumbents

• Dexcom: Leading CGM manufacturer and current Diabeloop CGM partner (G6/G7); owns its own algorithmic assets (acquired TypeZero) and represents both a critical partner and a strategic risk as it deepens AID capability internally.
• Roche Diabetes Care: Long-standing Diabeloop distribution and integration partner via the Accu-Chek Insight pump; a broader incumbent in BGM/CGM/pump that competes in the broader diabetes management landscape.
• Abbott Diabetes Care: Maker of the FreeStyle Libre CGM and ecosystem player; absorbed Bigfoot Biomedical and is a strategic competitor as it develops its own AID-capable ecosystem adjacent to Diabeloop's CGM partner Dexcom.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/diabeloop
• YouTubeyoutube.com/channel/UCBUWDaT02lXMP5eYGKKzTxA
• Facebookfacebook.com/diabeloop
• LinkedInlinkedin.com/company/diabeloop
• Instagraminstagram.com/diabeloop

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diabeloop